Markus Thunecke

“Is biopharma ready to embrace the new biology?”

Dr. Markus Thunecke Senior Partner
Graham Scholefield

“Sitting at the boundary between science and business is an incredibly rewarding experience”

DLI 150326_Catenion_8264

“We help our clients to achieve best practise in managing R&D performance”

Sophie von Dyrander

“My decision to join Catenion? Here I found what I was looking for – high level strategy work, international clients and the team spirit of a smaller firm.”

Matthias Krings

“Change-Management is a team effort – let’s get started”

Dr. Matthias Krings Senior Partner
Christian Elze

“China’s policy makers are making a concerted long-term effort to build a competitive biomedical innovation system – but R&D-based value creation
is only just beginning.”

Christian Elze Senior Partner
AHN 150326_Catenion_8344

“Translating new technologies into viable business ideas”

Arno Heuermann COO, Partner, Managing Director
COG 150326_Catenion_0233

“I help R&D teams deliver on the promise of gene therapy”


Biopharma’s Brave New Biology

The Medicine Maker – January 2016 - We live in exciting times for the biopharma industry. The 100-year-old promise of cancer immunotherapy turning cancer into a chronic (if not curable) disease seems within reach in selected indications. …
Download this article

Car-T cell therapy, looking beyond the hype!

While CAR-Ts have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as a whole and can justify current valuations and investor interest.

Meet Us

Jan. 7.-9., 2016

East/West CEO, Boston

Jan. 25th-27th, 2016

Strategic Project & Portfolio Management for Pharma, Spain, Barcelona

Jan. 30, 2016

The Future of Biopharmaceutical Innovation – The New York Academy of Sciences

Mar. 3rd & 4th, 2016

Pharma PPM Toolbox, Switzerland, Basel